DarioHealth to Report Third Quarter 2026 Results on Thursday, November 12, 2026
Company to host conference call and webcast at 8:30 a.m. Eastern Time
NEW YORK, Nov. 2, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leading artificial intelligence ("AI")-powered healthcare technology company transforming the management of chronic conditions, announced today that it will release its financial results for the 3rd quarter ended September 30th, 2026 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Thursday, November 12th, 2026, before the market opens.
Erez Raphael, Chief Executive Officer, Lara Dodo, Chief Operations Officer, and Chen Franco-Yehuda, Chief Financial Officer, will host the call.
Conference Call Details
Date: Thursday, November 12th, 2026, 8:30 a.m. Eastern Time
Dial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international)
Call me™: https://emportal.ink/4623c5K
Participants can use the dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. This link will be made active 15 minutes prior to the scheduled start time.
Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1775359&tp_key=4596015d94
Participants are asked to dial in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately three hours after completion of the conference call through Thursday, November 26th, 2026. To listen to the replay, dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and use replay passcode 1139413.
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is an AI-powered healthcare technology company helping health plans, health systems and employers improve health outcomes while lowering the cost of care. The Company's integrated platform combines connected devices, personalized member engagement, AI-driven insights and provider-backed clinical care to support people living with conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health needs.
Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, Dario's AI platform personalizes care at the individual member level by analyzing biometric, clinical and behavioral data to deliver more timely and effective interventions. By combining engagement, clinical intelligence and care delivery within a single platform, Dario helps customers address multiple chronic conditions through one solution.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expected date of its earnings release. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contact
Zoe Harrison
VP, Accounting and Corporate Development
irteam@dariohealth.com
DarioHealth Investor Relations Contact
Michael Lipari
SVP Corporate Development
irteam@dariohealth.com
+1-203-785-6310
View original content to download multimedia:https://www.prnewswire.com/news-releases/dariohealth-to-report-third-quarter-2026-results-on-thursday-november-12-2026-302926087.html
This press release may not be republished, redistributed, resold or sublicensed without the prior written approval of PR Newswire.
AlphAI analysis
Written by AlphAI from the release above, not by the issuer or PR Newswire. Informational, not investment advice.
The 30-second read
Why it matters
The announcement sets the stage for a typical earnings‑driven price swing; investors will watch for guidance changes, product updates, or regulatory news disclosed during the call.
Market read
Earnings‑date announcements are standard but provide a concrete timing cue for traders to position ahead of potential volatility.
What to watch
Potential regulatory updates or product launches that could be disclosed during the call may drive the move more than the earnings numbers themselves.
Background
DarioHealth is an AI‑driven healthcare technology company that provides chronic‑condition management platforms to health plans, systems, and employers.
Ticker impact
DarioHealth announced it will release its Q3 2026 earnings on November 12, 2026 before the market opens.
potential volatility as the market digests the earnings numbers when released
No financial figures are disclosed yet; the catalyst is the upcoming earnings call, which typically moves the stock around the release.
Market effects
Highlights continued activity in the AI‑enabled health‑tech sector ahead of earnings season.
U.S. market participants may adjust exposure to health‑tech stocks before the open.
Limited; primarily affects U.S. listed health‑tech investors.
Counterpoint
If the market over‑reacts to the earnings date, a contrarian could short on the hype and buy on any post‑release dip.
Key entities
- companyDarioHealth Corp.
NASDAQ‑listed AI health‑tech firm (ticker DRIO).
- executiveErez Raphael
Chief Executive Officer of DarioHealth.